WuXi Biologics provides contract research, development, and manufacturing services for biologics, offering end-to-end solutions from discovery to commercialization.

WuXi Biologics

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Analytics

DNSSEC

Chief Executive Officer

Jian Dong

VP, Biomanufacturing

Alan Wong

VP, Head of Protein Sciences

Jiansheng Wu

Senior Vice President of WuXi Biologics Manufacturing 11 & 18 US Operations

Jie Chen

Senior Vice President

Jing Li

Senior Vice President, Head of China Manufacturing

Keqiang Shen

VP of China and APAC Business Development

Liang Tang

Vice President, Biologics Downstream Process Development

Shiwen Lin

Vice President, Head of BioDev US

Wenjie Cheng

Operations

Xuejun (Sherry) Gu

Shaymaa Taieb

Associate Director, upstream Continious Manufacturing

Weichang Zhou

Chief Technology Officer & Executive Vice President

Christine Lu-Wong

Chief Financial Officer & Executive Vice President

Zhisheng Chen

Inhibrx is a clinical-stage biotechnology company that focuses on developing a broad pipeline of biologic therapeutic candidates.

Invetx is a veterinary therapeutics company that develops protein-based therapeutics for the treatment of various animal diseases.

Investors Active in La Jolla, California

China Companies With More Than $10M in Revenue

Biotechnology Companies With More Than $500 in Revenue

Health Care Companies With More Than $1B in Revenue

WuXi Biologics is a  open-access technology platform company offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. Across the global biologics research and development community, we enable our partners to find innovative biological treatments for diseases worldwide.

Venture Round - WuXi Biologics

Computer and Software Services and Scientific Services

Wuxi

Anhui

China

Asia

Single-Use Bioreactors Market anticipated to reach US$7.258 billion by 2030 at a CAGR of 14.55%

Lonza expands bioconjugates factory; WuXi Bio adds capacity in Germany

WuXi Biologics Launches WuXia™ RidGS for Non-Antibiotic Cell Line Development

WuXi Biologics Included in Hang Seng ESG 50 Index

Wuxi Biologics ADR Non-GAAP EPS of RMB0.52, revenue of RMB8.57B (Pink Current Info:WXXWY)

WuXi Biologics’ ADC spinout reports revenue jump despite Biosecure risk

WuXi Biologics and Medigene Enter into a Research Collaboration for Off-the-Shelf TCR-Guided T Cell Engagers

WuXi Biologics receives EMA approval for five facilities in China

WuXi AppTec and WuXi Biologics shares jumped after SmartKarma analyst Criss Wang

China's WuXi Biologics hits near 3-week peak after shares buyback

Ireland

Europe

United States

North America

Germany

United Kingdom

WuXi Biologics (Cayman) Inc. provides end-to-end solutions and services for biologics discovery, development and manufacturing in the People's Republic of China, North America, Europe, and internationally. The company also engages in the provision of consultation services in relation to the biopharmaceutical technology, international sales contracting services, testing and development of testing technologies, sales and marketing services, and biologics clinical and manufacturing services; production and sale of medicals; vaccine CDMO and related business; and material supplier activities. WuXi Biologics (Cayman) Inc. has strategic partnership with ImmuneOncia Therapeutics, Legochem Biosciences Inc, Worg Pharma, OncoC4, and Exelixis Inc. The company was incorporated in 2014 and is headquartered in Wuxi, China.

WuXi Biologics (Cayman) Inc.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Sep 28, 2024 1:26 PM	3c9e8662
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Sep 28, 2024 1:26 PM	d45bd735
crunchbase trigger	general	Nov 25, 2024 9:06 AM	9e2b7659
crunchbase profile	general	Nov 25, 2024 12:41 PM	60ccc034
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 3:04 PM	4f68fa50
peers	general	Sep 28, 2024 1:26 PM	83431db3
news basic	general	Sep 28, 2024 1:26 PM	db5cf416
bundesanzeiger	filings
financials download nd	financials
private financials	financials

2269

COM:WUXIBIOLOGICS

WuXi Biologics

Last Close

14.40

25/11 08:08

Market Cap

46.18B

Beta: -

Volume Today

45.60M

Avg: -